Lieberman A, Zolfaghari M, Boal D, Hassouri H, Vogel B, Battista A, Fuxe K, Goldstein M
Neurology. 1976 May;26(5):405-9. doi: 10.1212/wnl.26.5.405.
The antiparkinsonian activity of bromocriptine, a presumed dopaminergic receptor agonist, was investigated in monkeys with surgically induced tremor and in a group of parkinsonian patients. A single administration of bromocriptine resulted in a dose-dependent relief of tremor in monkeys. Repeated administration enhanced this effect. Only mild abnormal involuntary movements were observed and only after repeated administration. Eleven patients with Parkinson's disease were treated with bromocriptine (mean dose, 26.4 mg a day). Clinically obvious improvement was noted in one or more of the cardinal signs of the disease in six patients (responders). No obvious improvement in any of the cardinal signs was noted in the remaining five patients (nonresponders). Clinically, the responders were older and more severely affected and had been on a higher dose of levodopa. However, they had had the disease for a shorter period. It is suggested that failure to respond to bromocriptine may be related to a decrease in the sensitivity of postsynaptic dopaminergic receptors.
对一种假定的多巴胺能受体激动剂——溴隐亭的抗帕金森病活性，在手术诱发震颤的猴子和一组帕金森病患者中进行了研究。单次给予溴隐亭可使猴子的震颤得到剂量依赖性缓解。重复给药可增强这种效果。仅在重复给药后才观察到轻度异常不自主运动。11例帕金森病患者接受了溴隐亭治疗（平均剂量为每日26.4毫克）。6例患者（有反应者）在该疾病的一项或多项主要体征上有明显临床改善。其余5例患者（无反应者）在任何主要体征上均未观察到明显改善。临床上，有反应者年龄较大、病情较重，且服用左旋多巴的剂量较高。然而，他们患该病的时间较短。提示对溴隐亭无反应可能与突触后多巴胺能受体敏感性降低有关。
